Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma.

Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. Curr Cancer Drug Targets. 2017 Sep 06;: Authors: Atanackovic D, Luetkens T, Steinbach M, Kröger N Abstract Immunological dysfunction in the microenvironment of multiple myeloma is a potential target for immune-mediated therapies. The programmed death 1 (PD-1) receptor is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on tumor cells and inhibits T-cell-mediated apoptosis. Inhibiting such "checkpoint" by monoclonal antibodies recently has been shown high activity in solid tumors and malignant lymphomas. In patients with multiple myeloma PD-L1 is overexpressed on myeloma cells and PD1 on T-cells suggesting an active role of PD- 1/PD-L1 in the immunosuppressive microenvironment. PMID: 28875836 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research